查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1791760

全球眼科临床试验市场

Ophthalmic Clinical Trials
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 162 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

预计到 2030 年全球眼科临床试验市场规模将达 27 亿美元

全球眼科临床试验市场规模预计在2024年达到18亿美元，预计在2024-2030年的分析期内将以6.3%的复合年增长率增长，到2030年将达到27亿美元。眼科临床试验药物是本报告分析的细分市场之一，预计其复合年增长率将达到7.1%，到分析期末将达到20亿美元。眼科临床试验设备细分市场在分析期间的复合年增长率预计为4.2%。

美国市场规模估计为 4.838 亿美元，中国市场预计复合年增长率为 6.1%

美国眼科临床试验市场规模预计2024年达到4.838亿美元。预计到2030年，作为世界第二大经济体的中国市场规模将达到4.261亿美元，在分析期间（2024-2030年）的复合年增长率为6.1%。其他值得关注的区域市场包括日本和加拿大，预计在分析期间的复合年增长率分别为6.0%和5.3%。在欧洲，预计德国的复合年增长率为5.0%。

全球眼科临床试验市场－主要趋势与驱动因素摘要

为什么眼科是临床研究的温床？

眼科学领域正在经历模式转移，旨在应对全球眼部疾病上升的临床研究活动激增。由于老龄化黄斑部病变(AMD)、糖尿病视网膜病变、青光眼和干眼症等疾病负担的增加，眼科临床试验正以前所未有的速度扩大。全球人口老化是这一趋势的主要驱动因素，视力相关疾病的盛行率随着老龄化的增长而急剧上升。同时，糖尿病和长时间使用萤幕等生活方式相关的风险因素正在推动对治疗创新的需求。眼科学的独特之处在于可以直接观察和精确测量疾病进展，有助于准确的结果评估，使其成为对製药和生物技术公司特别有吸引力的领域。加速研究的另一个因素是我们对基因和分子层面的眼部病理学的理解不断加深，从而能够进行更有针对性和个性化的治疗。此外，与其他治疗领域的临床试验相比，眼科临床试验由于终点明确且诊断工具标准化，通常招募速度快、时间短。这使得眼科临床试验在各个阶段都拥有丰富的研发管线，许多产业领导者和灵活的新兴企业正在投资下一代药物、基因疗法、缓释性植入和再生医学方法。

试验设计的创新如何影响眼科研究？

在眼科领域，技术进步以及对高效、以患者为中心的方法日益增长的需求，正在从根本上改变临床试验设计的传统模式。自适应试验设计允许根据中期数据修改方案，因其灵活性和高效性而日益普及。同样，分散式和混合式临床试验模式能够扩大患者入组范围，尤其是在地理分散、难以获得专业眼科护理的人群中。行动眼科影像、远距视力检查应用程式和穿戴式眼压监测仪等数位健康工具的整合，正在将即时监测功能引入临床试验，减少对门诊就诊的依赖，并提高数据收集的准确性。人工智慧 (AI) 和机器学习演算法正被用于分析影像生物标记并预测病情进展，从而优化患者选择和终点确定。此类技术整合还有助于实现临床试验工作流程、法规提交和病患监测流程的自动化，显着减少时间和成本负担。此外，在试验设计中，越来越重视使用真实世界数据 (RWD) 和真实世界证据 (RWE)，以增强外部效度和监管效度。随着 FDA 和 EMA 等监管机构对创新临床试验模式的开放程度不断提高，申办者也感到更有信心尝试新方法，从而推动眼科临床试验的进一步现代化。

哪些相关人员正在推动各个治疗领域的需求？

眼科临床试验的需求由众多相关人员推动，每个利害关係人在塑造研究生态系统方面都发挥着独特而又互补的作用。製药和生物技术公司处于前沿，致力于开发针对常见和罕见眼科疾病眼科疾病的新型疗法。该行业正日益从治疗症状转向改变和预防疾病，为抗VEGF药物、基因疗法和干细胞疗法等尖端治疗方法打开了大门。眼科专业委外研发机构(CRO) 也正在成为重要的合作伙伴，在研究设计、病患招募和全球监管标准合规方面提供专业知识。学术和研究机构仍然是早期发现和转化研究的中心，它们经常与产业相关人员组成联盟以加速临床开发。患者权益组织和非营利组织在製定临床试验优先事项方面的影响力日益增强，确保在临床实验方案中解决以患者为中心的结果和可及性问题。另一个主要驱动因素是创业投资和私募股权公司不断增加的投资，它们正在积极资助临床实验新创新兴企业和平台技术。在医疗保健服务方面，综合眼科护理创业投资和专科眼科股权在开展临床实验试验方面发挥关键作用，它们能够提供精准的患者群体和高品质的诊断基础设施。这种多方相关人员的参与不仅拓宽了临床实验的格局，也确保了创新具有临床相关性和商业性可行性。

推动眼科临床试验市场成长的具体趋势有哪些？

眼科临床试验市场的成长受到与不断发展的治疗需求、技术力和行业实践相关的多种因素的驱动。一个关键的成长要素是针对孤立性视网膜疾病的精准医疗和基因治疗平台的快速发展，这需要专门的试验设计和监管途径。糖尿病等慢性全身性疾病的盛行率不断上升，推动了以糖尿病黄斑部水肿和糖尿病视网膜病变为重点的临床试验。此外，全球数位萤幕使用量的激增导致干眼症和近视的增加，促使人们广泛研究新的治疗方法。光同调断层扫瞄(OCT)、眼底萤光和微视野等技术的进步正在提高终点准确性并且能够对治疗效果进行更细緻的评估。临床试验的全球化也是一个关键驱动因素，申办方越来越多地瞄准亚太、拉丁美洲和东欧的新兴市场，这些市场提供大量患者群和快速招募週期。监管机构正在透过加速审查机制、有条件核准和孤儿药认定来简化眼科临床试验的审批核准，进一步奖励创新。电子健康记录和巨量资料分析的日益普及也有助于场地选择、可行性评估和长期患者追踪。最后，对生活品质 (QoL) 指标和患者报告结果的日益重视，使眼科临床试验与更广泛的医疗保健价值框架相一致，从而满足临床和社会的期望。

部分

产品（眼科临床试验药物、眼科临床试验设备）；阶段（临床阶段、探索阶段、临床前阶段）；申办者（製药/生物製药公司、医疗设备公司、其他申办者）

受访公司范例

  • Charles River Laboratories
  • CMIC Group
  • Covance Inc.
  • ICON plc
  • IQVIA
  • Iris Pharma
  • KCR
  • Labcorp Drug Development
  • Medpace
  • Novotech
  • Ora, Inc.
  • Parexel International
  • PPD（Pharmaceutical Product Development）
  • PRA Health Sciences
  • PRC Clinical
  • QuintilesIMS
  • Syneos Health
  • TFS HealthScience
  • Worldwide Clinical Trials
  • WuXi AppTec

人工智慧集成

我们正在利用有效的专家内容和人工智慧工具来改变市场和竞争情报。

Global Industry Analysts 没有遵循查询 LLM 或特定产业SLM 的典型规范，而是建立了一个来自世界各地专家的精选内容库，其中包括视频录像、博客、搜寻引擎研究以及大量的公司、产品/服务和市场数据。

关税影响係数

全球产业分析师根据公司总部所在国家、製造地和进出口（成品和原始设备製造商）情况预测其竞争地位的变化。这种复杂而多面的市场动态预计将以多种方式影响竞争对手，包括销货成本(COGS) 上升、盈利下降、供应链重组以及其他微观和宏观市场动态。

目录

第一章调查方法

第二章执行摘要

  • 市场概览
  • 主要企业
  • 市场趋势和驱动因素
  • 全球市场展望

第三章市场分析

  • 美国
  • 加拿大
  • 日本
  • 中国
  • 欧洲
  • 法国
  • 德国
  • 义大利
  • 英国
  • 其他欧洲国家
  • 亚太地区
  • 其他地区

第四章 竞赛

简介目录
Product Code: MCP32424

Global Ophthalmic Clinical Trials Market to Reach US$2.7 Billion by 2030

The global market for Ophthalmic Clinical Trials estimated at US$1.8 Billion in the year 2024, is expected to reach US$2.7 Billion by 2030, growing at a CAGR of 6.3% over the analysis period 2024-2030. Ophthalmic Clinical Trial Drugs, one of the segments analyzed in the report, is expected to record a 7.1% CAGR and reach US$2.0 Billion by the end of the analysis period. Growth in the Ophthalmic Clinical Trial Devices segment is estimated at 4.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$483.8 Million While China is Forecast to Grow at 6.1% CAGR

The Ophthalmic Clinical Trials market in the U.S. is estimated at US$483.8 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$426.1 Million by the year 2030 trailing a CAGR of 6.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 6.0% and 5.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.0% CAGR.

Global Ophthalmic Clinical Trials Market - Key Trends & Drivers Summarized

What Makes Ophthalmology a Hotbed for Clinical Research Today?

The field of ophthalmology is undergoing a paradigm shift, with a surge in clinical research activity aimed at combating the global rise in eye-related disorders. Ophthalmic clinical trials are expanding at an unprecedented pace, driven by the increasing burden of diseases such as age-related macular degeneration (AMD), diabetic retinopathy, glaucoma, and dry eye syndrome. The aging global population is a major contributor to this trend, as the prevalence of vision-related impairments escalates sharply with age. At the same time, lifestyle-related risk factors like diabetes and prolonged screen time are amplifying the need for therapeutic innovations. Ophthalmology is unique in that it allows for direct visualization and precise measurement of disease progression, which facilitates accurate outcome assessment-making it especially attractive for pharmaceutical and biotech companies. Another factor accelerating research is the evolving understanding of ocular pathophysiology at the genetic and molecular levels, enabling more targeted and individualized therapies. Furthermore, ophthalmic trials often involve faster recruitment and shorter timelines compared to trials in other therapeutic areas, due to well-defined endpoints and standardized diagnostic tools. This has attracted a mix of industry giants and nimble startups to invest in next-generation drugs, gene therapies, sustained-release implants, and regenerative medicine approaches, creating a rich pipeline of ophthalmic clinical trials across all phases.

How Are Innovations in Trial Design Reshaping Ophthalmic Research?

The traditional paradigms of clinical trial design are being radically transformed in the ophthalmology sector, spurred by technological advancements and the rising need for efficient, patient-centric methodologies. Adaptive trial designs, which allow for protocol modifications based on interim data, are gaining popularity for their flexibility and efficiency. Similarly, decentralized and hybrid clinical trial models are enabling broader patient participation, especially in geographically dispersed populations where access to specialized eye care is limited. The integration of digital health tools-such as mobile ophthalmic imaging, remote vision testing apps, and wearable intraocular pressure monitors-has brought real-time monitoring capabilities into clinical trials, reducing reliance on in-clinic visits and improving data collection accuracy. Artificial intelligence (AI) and machine learning algorithms are being deployed to analyze imaging biomarkers and predict disease progression, thereby optimizing both patient selection and endpoint determination. These technological integrations are also helping in the automation of trial workflows, regulatory submissions, and patient monitoring processes, significantly reducing time and cost burdens. Moreover, there is growing emphasis on using real-world data (RWD) and real-world evidence (RWE) in trial design to enhance external validity and regulatory relevance. As regulators such as the FDA and EMA show increasing openness to innovative trial models, sponsors are feeling more empowered to experiment with novel approaches, driving further modernization across ophthalmic clinical trials.

Which Stakeholders Are Driving Demand Across Diverse Therapeutic Fronts?

The demand for ophthalmic clinical trials is being propelled by a broad spectrum of stakeholders, each playing a distinct yet complementary role in shaping the research ecosystem. Pharmaceutical and biotechnology companies are at the forefront, striving to develop novel therapeutics that address both common and rare ocular diseases. Increasingly, there is an industry-wide shift from treating symptoms to disease modification and prevention, which has opened the door for cutting-edge therapies such as anti-VEGF agents, gene therapies, and stem cell-based interventions. Contract Research Organizations (CROs) specializing in ophthalmology have also emerged as pivotal partners, providing expertise in study design, patient recruitment, and compliance with global regulatory standards. Academic and research institutions continue to be hubs for early-stage discovery and translational research, often working in consortia with industry players to accelerate clinical development. Patient advocacy groups and nonprofit organizations are becoming influential in shaping trial priorities, ensuring that patient-centric outcomes and accessibility concerns are addressed in study protocols. Another significant driver is the rising investment from venture capital and private equity firms, which are actively funding ophthalmic startups and platform technologies. On the healthcare delivery front, integrated eye care networks and specialized ophthalmology clinics are playing a crucial role in trial execution, offering access to well-characterized patient populations and high-quality diagnostic infrastructure. The involvement of these multifaceted stakeholders is not only expanding the trial landscape but also ensuring that innovations are clinically meaningful and commercially viable.

What Specific Trends Are Accelerating Growth in the Ophthalmic Trials Market?

The growth in the ophthalmic clinical trials market is driven by several factors related to evolving therapeutic needs, technological capabilities, and industry practices. A key growth driver is the rapid development of precision medicine and gene therapy platforms tailored for monogenic retinal diseases, which require specialized trial designs and regulatory pathways. The rising incidence of chronic systemic diseases like diabetes is fueling trials focused on diabetic macular edema and diabetic retinopathy. Additionally, the global surge in digital screen usage is contributing to an increase in dry eye syndrome and myopia, prompting extensive research into novel treatment modalities. Technological advancements such as optical coherence tomography (OCT), fundus autofluorescence, and microperimetry are enhancing endpoint precision and enabling more nuanced evaluations of treatment efficacy. The globalization of clinical trials is another critical factor, with sponsors increasingly targeting emerging markets in Asia-Pacific, Latin America, and Eastern Europe to tap into large patient pools and faster recruitment cycles. Regulatory agencies are streamlining ophthalmic trial approvals through accelerated review mechanisms, conditional approvals, and orphan drug designations, further incentivizing innovation. The growing use of electronic health records and big data analytics is also supporting site selection, feasibility assessments, and long-term patient follow-up. Lastly, an increasing emphasis on quality of life (QoL) metrics and patient-reported outcomes is aligning ophthalmic trials with broader healthcare value frameworks, ensuring they meet both clinical and societal expectations.

SCOPE OF STUDY:

The report analyzes the Ophthalmic Clinical Trials market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (Ophthalmic Clinical Trial Drugs, Ophthalmic Clinical Trial Devices); Phase (Clinical Phase, Discovery Phase, Preclinical Phase); Sponsor (Pharmaceutical / Biopharmaceutical Companies, Medical Device Companies, Other Sponsors)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 32 Featured) -

  • Charles River Laboratories
  • CMIC Group
  • Covance Inc.
  • ICON plc
  • IQVIA
  • Iris Pharma
  • KCR
  • Labcorp Drug Development
  • Medpace
  • Novotech
  • Ora, Inc.
  • Parexel International
  • PPD (Pharmaceutical Product Development)
  • PRA Health Sciences
  • PRC Clinical
  • QuintilesIMS
  • Syneos Health
  • TFS HealthScience
  • Worldwide Clinical Trials
  • WuXi AppTec

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Ophthalmic Clinical Trials - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of Vision Disorders Throws the Spotlight on Accelerated Ophthalmic Drug Development
    • Advances in Ocular Imaging Technologies Spur Growth in Precision-Driven Clinical Trial Endpoints
    • Patient-Centric Trial Models Expand Addressable Market Opportunity for Remote and Hybrid Ophthalmic Studies
    • Increased Focus on Rare and Genetic Eye Diseases Strengthens the Business Case for Specialized Trials
    • Biotech and Pharma Collaboration Accelerates Demand for Outsourced Ophthalmic Research Expertise
    • Digital Health Tools and Wearables Generate Opportunities for Real-Time Monitoring in Ophthalmic Trials
    • Artificial Intelligence in Image Analysis Enhances Efficiency and Accuracy of Clinical Outcome Assessments
    • Pediatric and Geriatric Trial Demographics Propel Growth in Age-Specific Study Designs and Delivery Models
    • Rising Investments in Gene Therapy and Regenerative Medicine Drive the Need for Complex Ophthalmic Trials
    • Globalization of Clinical Research Sites Sustains Growth by Broadening Access to Diverse Patient Populations
    • Risk-Based Monitoring and eSource Technologies Drive Adoption of Decentralized Clinical Trial Frameworks
    • Increased Emphasis on Quality-of-Life Metrics Generates Demand for Holistic Trial Outcomes Beyond Vision Acuity
    • Growing Involvement of Advocacy Groups and Patient Registries Strengthens Recruitment and Retention Strategies
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Ophthalmic Clinical Trials Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Ophthalmic Clinical Trials by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World 6-Year Perspective for Ophthalmic Clinical Trials by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Ophthalmic Clinical Trial Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 5: World 6-Year Perspective for Ophthalmic Clinical Trial Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Ophthalmic Clinical Trial Devices by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 7: World 6-Year Perspective for Ophthalmic Clinical Trial Devices by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Clinical Phase by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World 6-Year Perspective for Clinical Phase by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Discovery Phase by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 11: World 6-Year Perspective for Discovery Phase by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Preclinical Phase by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 13: World 6-Year Perspective for Preclinical Phase by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Pharmaceutical / Biopharmaceutical Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World 6-Year Perspective for Pharmaceutical / Biopharmaceutical Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Medical Device Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 17: World 6-Year Perspective for Medical Device Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for Other Sponsors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 19: World 6-Year Perspective for Other Sponsors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Ophthalmic Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 20: USA Recent Past, Current & Future Analysis for Ophthalmic Clinical Trials by Product - Ophthalmic Clinical Trial Drugs and Ophthalmic Clinical Trial Devices - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 21: USA 6-Year Perspective for Ophthalmic Clinical Trials by Product - Percentage Breakdown of Value Sales for Ophthalmic Clinical Trial Drugs and Ophthalmic Clinical Trial Devices for the Years 2025 & 2030
    • TABLE 22: USA Recent Past, Current & Future Analysis for Ophthalmic Clinical Trials by Phase - Clinical Phase, Discovery Phase and Preclinical Phase - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 23: USA 6-Year Perspective for Ophthalmic Clinical Trials by Phase - Percentage Breakdown of Value Sales for Clinical Phase, Discovery Phase and Preclinical Phase for the Years 2025 & 2030
    • TABLE 24: USA Recent Past, Current & Future Analysis for Ophthalmic Clinical Trials by Sponsor - Pharmaceutical / Biopharmaceutical Companies, Medical Device Companies and Other Sponsors - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 25: USA 6-Year Perspective for Ophthalmic Clinical Trials by Sponsor - Percentage Breakdown of Value Sales for Pharmaceutical / Biopharmaceutical Companies, Medical Device Companies and Other Sponsors for the Years 2025 & 2030
  • CANADA
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Ophthalmic Clinical Trials by Product - Ophthalmic Clinical Trial Drugs and Ophthalmic Clinical Trial Devices - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Canada 6-Year Perspective for Ophthalmic Clinical Trials by Product - Percentage Breakdown of Value Sales for Ophthalmic Clinical Trial Drugs and Ophthalmic Clinical Trial Devices for the Years 2025 & 2030
    • TABLE 28: Canada Recent Past, Current & Future Analysis for Ophthalmic Clinical Trials by Phase - Clinical Phase, Discovery Phase and Preclinical Phase - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 29: Canada 6-Year Perspective for Ophthalmic Clinical Trials by Phase - Percentage Breakdown of Value Sales for Clinical Phase, Discovery Phase and Preclinical Phase for the Years 2025 & 2030
    • TABLE 30: Canada Recent Past, Current & Future Analysis for Ophthalmic Clinical Trials by Sponsor - Pharmaceutical / Biopharmaceutical Companies, Medical Device Companies and Other Sponsors - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 31: Canada 6-Year Perspective for Ophthalmic Clinical Trials by Sponsor - Percentage Breakdown of Value Sales for Pharmaceutical / Biopharmaceutical Companies, Medical Device Companies and Other Sponsors for the Years 2025 & 2030
  • JAPAN
    • Ophthalmic Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Ophthalmic Clinical Trials by Product - Ophthalmic Clinical Trial Drugs and Ophthalmic Clinical Trial Devices - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Japan 6-Year Perspective for Ophthalmic Clinical Trials by Product - Percentage Breakdown of Value Sales for Ophthalmic Clinical Trial Drugs and Ophthalmic Clinical Trial Devices for the Years 2025 & 2030
    • TABLE 34: Japan Recent Past, Current & Future Analysis for Ophthalmic Clinical Trials by Phase - Clinical Phase, Discovery Phase and Preclinical Phase - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 35: Japan 6-Year Perspective for Ophthalmic Clinical Trials by Phase - Percentage Breakdown of Value Sales for Clinical Phase, Discovery Phase and Preclinical Phase for the Years 2025 & 2030
    • TABLE 36: Japan Recent Past, Current & Future Analysis for Ophthalmic Clinical Trials by Sponsor - Pharmaceutical / Biopharmaceutical Companies, Medical Device Companies and Other Sponsors - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 37: Japan 6-Year Perspective for Ophthalmic Clinical Trials by Sponsor - Percentage Breakdown of Value Sales for Pharmaceutical / Biopharmaceutical Companies, Medical Device Companies and Other Sponsors for the Years 2025 & 2030
  • CHINA
    • Ophthalmic Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 38: China Recent Past, Current & Future Analysis for Ophthalmic Clinical Trials by Product - Ophthalmic Clinical Trial Drugs and Ophthalmic Clinical Trial Devices - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: China 6-Year Perspective for Ophthalmic Clinical Trials by Product - Percentage Breakdown of Value Sales for Ophthalmic Clinical Trial Drugs and Ophthalmic Clinical Trial Devices for the Years 2025 & 2030
    • TABLE 40: China Recent Past, Current & Future Analysis for Ophthalmic Clinical Trials by Phase - Clinical Phase, Discovery Phase and Preclinical Phase - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 41: China 6-Year Perspective for Ophthalmic Clinical Trials by Phase - Percentage Breakdown of Value Sales for Clinical Phase, Discovery Phase and Preclinical Phase for the Years 2025 & 2030
    • TABLE 42: China Recent Past, Current & Future Analysis for Ophthalmic Clinical Trials by Sponsor - Pharmaceutical / Biopharmaceutical Companies, Medical Device Companies and Other Sponsors - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 43: China 6-Year Perspective for Ophthalmic Clinical Trials by Sponsor - Percentage Breakdown of Value Sales for Pharmaceutical / Biopharmaceutical Companies, Medical Device Companies and Other Sponsors for the Years 2025 & 2030
  • EUROPE
    • Ophthalmic Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Ophthalmic Clinical Trials by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 45: Europe 6-Year Perspective for Ophthalmic Clinical Trials by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 46: Europe Recent Past, Current & Future Analysis for Ophthalmic Clinical Trials by Product - Ophthalmic Clinical Trial Drugs and Ophthalmic Clinical Trial Devices - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 47: Europe 6-Year Perspective for Ophthalmic Clinical Trials by Product - Percentage Breakdown of Value Sales for Ophthalmic Clinical Trial Drugs and Ophthalmic Clinical Trial Devices for the Years 2025 & 2030
    • TABLE 48: Europe Recent Past, Current & Future Analysis for Ophthalmic Clinical Trials by Phase - Clinical Phase, Discovery Phase and Preclinical Phase - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 49: Europe 6-Year Perspective for Ophthalmic Clinical Trials by Phase - Percentage Breakdown of Value Sales for Clinical Phase, Discovery Phase and Preclinical Phase for the Years 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Ophthalmic Clinical Trials by Sponsor - Pharmaceutical / Biopharmaceutical Companies, Medical Device Companies and Other Sponsors - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe 6-Year Perspective for Ophthalmic Clinical Trials by Sponsor - Percentage Breakdown of Value Sales for Pharmaceutical / Biopharmaceutical Companies, Medical Device Companies and Other Sponsors for the Years 2025 & 2030
  • FRANCE
    • Ophthalmic Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 52: France Recent Past, Current & Future Analysis for Ophthalmic Clinical Trials by Product - Ophthalmic Clinical Trial Drugs and Ophthalmic Clinical Trial Devices - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 53: France 6-Year Perspective for Ophthalmic Clinical Trials by Product - Percentage Breakdown of Value Sales for Ophthalmic Clinical Trial Drugs and Ophthalmic Clinical Trial Devices for the Years 2025 & 2030
    • TABLE 54: France Recent Past, Current & Future Analysis for Ophthalmic Clinical Trials by Phase - Clinical Phase, Discovery Phase and Preclinical Phase - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 55: France 6-Year Perspective for Ophthalmic Clinical Trials by Phase - Percentage Breakdown of Value Sales for Clinical Phase, Discovery Phase and Preclinical Phase for the Years 2025 & 2030
    • TABLE 56: France Recent Past, Current & Future Analysis for Ophthalmic Clinical Trials by Sponsor - Pharmaceutical / Biopharmaceutical Companies, Medical Device Companies and Other Sponsors - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France 6-Year Perspective for Ophthalmic Clinical Trials by Sponsor - Percentage Breakdown of Value Sales for Pharmaceutical / Biopharmaceutical Companies, Medical Device Companies and Other Sponsors for the Years 2025 & 2030
  • GERMANY
    • Ophthalmic Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 58: Germany Recent Past, Current & Future Analysis for Ophthalmic Clinical Trials by Product - Ophthalmic Clinical Trial Drugs and Ophthalmic Clinical Trial Devices - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 59: Germany 6-Year Perspective for Ophthalmic Clinical Trials by Product - Percentage Breakdown of Value Sales for Ophthalmic Clinical Trial Drugs and Ophthalmic Clinical Trial Devices for the Years 2025 & 2030
    • TABLE 60: Germany Recent Past, Current & Future Analysis for Ophthalmic Clinical Trials by Phase - Clinical Phase, Discovery Phase and Preclinical Phase - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 61: Germany 6-Year Perspective for Ophthalmic Clinical Trials by Phase - Percentage Breakdown of Value Sales for Clinical Phase, Discovery Phase and Preclinical Phase for the Years 2025 & 2030
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Ophthalmic Clinical Trials by Sponsor - Pharmaceutical / Biopharmaceutical Companies, Medical Device Companies and Other Sponsors - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany 6-Year Perspective for Ophthalmic Clinical Trials by Sponsor - Percentage Breakdown of Value Sales for Pharmaceutical / Biopharmaceutical Companies, Medical Device Companies and Other Sponsors for the Years 2025 & 2030
  • ITALY
    • TABLE 64: Italy Recent Past, Current & Future Analysis for Ophthalmic Clinical Trials by Product - Ophthalmic Clinical Trial Drugs and Ophthalmic Clinical Trial Devices - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 65: Italy 6-Year Perspective for Ophthalmic Clinical Trials by Product - Percentage Breakdown of Value Sales for Ophthalmic Clinical Trial Drugs and Ophthalmic Clinical Trial Devices for the Years 2025 & 2030
    • TABLE 66: Italy Recent Past, Current & Future Analysis for Ophthalmic Clinical Trials by Phase - Clinical Phase, Discovery Phase and Preclinical Phase - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 67: Italy 6-Year Perspective for Ophthalmic Clinical Trials by Phase - Percentage Breakdown of Value Sales for Clinical Phase, Discovery Phase and Preclinical Phase for the Years 2025 & 2030
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Ophthalmic Clinical Trials by Sponsor - Pharmaceutical / Biopharmaceutical Companies, Medical Device Companies and Other Sponsors - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy 6-Year Perspective for Ophthalmic Clinical Trials by Sponsor - Percentage Breakdown of Value Sales for Pharmaceutical / Biopharmaceutical Companies, Medical Device Companies and Other Sponsors for the Years 2025 & 2030
  • UNITED KINGDOM
    • Ophthalmic Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 70: UK Recent Past, Current & Future Analysis for Ophthalmic Clinical Trials by Product - Ophthalmic Clinical Trial Drugs and Ophthalmic Clinical Trial Devices - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 71: UK 6-Year Perspective for Ophthalmic Clinical Trials by Product - Percentage Breakdown of Value Sales for Ophthalmic Clinical Trial Drugs and Ophthalmic Clinical Trial Devices for the Years 2025 & 2030
    • TABLE 72: UK Recent Past, Current & Future Analysis for Ophthalmic Clinical Trials by Phase - Clinical Phase, Discovery Phase and Preclinical Phase - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 73: UK 6-Year Perspective for Ophthalmic Clinical Trials by Phase - Percentage Breakdown of Value Sales for Clinical Phase, Discovery Phase and Preclinical Phase for the Years 2025 & 2030
    • TABLE 74: UK Recent Past, Current & Future Analysis for Ophthalmic Clinical Trials by Sponsor - Pharmaceutical / Biopharmaceutical Companies, Medical Device Companies and Other Sponsors - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK 6-Year Perspective for Ophthalmic Clinical Trials by Sponsor - Percentage Breakdown of Value Sales for Pharmaceutical / Biopharmaceutical Companies, Medical Device Companies and Other Sponsors for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 76: Rest of Europe Recent Past, Current & Future Analysis for Ophthalmic Clinical Trials by Product - Ophthalmic Clinical Trial Drugs and Ophthalmic Clinical Trial Devices - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 77: Rest of Europe 6-Year Perspective for Ophthalmic Clinical Trials by Product - Percentage Breakdown of Value Sales for Ophthalmic Clinical Trial Drugs and Ophthalmic Clinical Trial Devices for the Years 2025 & 2030
    • TABLE 78: Rest of Europe Recent Past, Current & Future Analysis for Ophthalmic Clinical Trials by Phase - Clinical Phase, Discovery Phase and Preclinical Phase - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 79: Rest of Europe 6-Year Perspective for Ophthalmic Clinical Trials by Phase - Percentage Breakdown of Value Sales for Clinical Phase, Discovery Phase and Preclinical Phase for the Years 2025 & 2030
    • TABLE 80: Rest of Europe Recent Past, Current & Future Analysis for Ophthalmic Clinical Trials by Sponsor - Pharmaceutical / Biopharmaceutical Companies, Medical Device Companies and Other Sponsors - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Rest of Europe 6-Year Perspective for Ophthalmic Clinical Trials by Sponsor - Percentage Breakdown of Value Sales for Pharmaceutical / Biopharmaceutical Companies, Medical Device Companies and Other Sponsors for the Years 2025 & 2030
  • ASIA-PACIFIC
    • Ophthalmic Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 82: Asia-Pacific Recent Past, Current & Future Analysis for Ophthalmic Clinical Trials by Product - Ophthalmic Clinical Trial Drugs and Ophthalmic Clinical Trial Devices - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 83: Asia-Pacific 6-Year Perspective for Ophthalmic Clinical Trials by Product - Percentage Breakdown of Value Sales for Ophthalmic Clinical Trial Drugs and Ophthalmic Clinical Trial Devices for the Years 2025 & 2030
    • TABLE 84: Asia-Pacific Recent Past, Current & Future Analysis for Ophthalmic Clinical Trials by Phase - Clinical Phase, Discovery Phase and Preclinical Phase - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 85: Asia-Pacific 6-Year Perspective for Ophthalmic Clinical Trials by Phase - Percentage Breakdown of Value Sales for Clinical Phase, Discovery Phase and Preclinical Phase for the Years 2025 & 2030
    • TABLE 86: Asia-Pacific Recent Past, Current & Future Analysis for Ophthalmic Clinical Trials by Sponsor - Pharmaceutical / Biopharmaceutical Companies, Medical Device Companies and Other Sponsors - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Asia-Pacific 6-Year Perspective for Ophthalmic Clinical Trials by Sponsor - Percentage Breakdown of Value Sales for Pharmaceutical / Biopharmaceutical Companies, Medical Device Companies and Other Sponsors for the Years 2025 & 2030
  • REST OF WORLD
    • TABLE 88: Rest of World Recent Past, Current & Future Analysis for Ophthalmic Clinical Trials by Product - Ophthalmic Clinical Trial Drugs and Ophthalmic Clinical Trial Devices - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 89: Rest of World 6-Year Perspective for Ophthalmic Clinical Trials by Product - Percentage Breakdown of Value Sales for Ophthalmic Clinical Trial Drugs and Ophthalmic Clinical Trial Devices for the Years 2025 & 2030
    • TABLE 90: Rest of World Recent Past, Current & Future Analysis for Ophthalmic Clinical Trials by Phase - Clinical Phase, Discovery Phase and Preclinical Phase - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 91: Rest of World 6-Year Perspective for Ophthalmic Clinical Trials by Phase - Percentage Breakdown of Value Sales for Clinical Phase, Discovery Phase and Preclinical Phase for the Years 2025 & 2030
    • TABLE 92: Rest of World Recent Past, Current & Future Analysis for Ophthalmic Clinical Trials by Sponsor - Pharmaceutical / Biopharmaceutical Companies, Medical Device Companies and Other Sponsors - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of World 6-Year Perspective for Ophthalmic Clinical Trials by Sponsor - Percentage Breakdown of Value Sales for Pharmaceutical / Biopharmaceutical Companies, Medical Device Companies and Other Sponsors for the Years 2025 & 2030

IV. COMPETITION